CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study-Reference-Cited by-同舟云学术

CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study

Published:2017-04 Issue:4 Volume:49 Page:434-439
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Sciarra Amedeo,Pintea Bogdan,Nahm Ji Hae,Donadon Matteo,Morenghi Emanuela,Maggioni Marco,Blanc Jean Frederic,Torzilli Guido,Yeh Matthew,Bioulac-Sage Paulette,Park Young Nyun,Roncalli Massimo,Di Tommaso Luca

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Epidemiology of hepatocellular carcinoma;Lafaro;Surgical Oncology Clinics of North America,2015

2. Primary liver cancer: worldwide incidence and trends;Bosch;Gastroenterology,2004

3. Prognosis of hepatocellular carcinoma: the BCLC staging classification;Llovet;Seminars in Liver Disease,1999

4. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes;Shah;Surgery,2007

5. Chemoembolization for intermediate HCC: is there proof of survival benefit;Forner;Journal of Hepatology,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib;Drug Metabolism and Disposition;2024-04-02

2. Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma;Asian Journal of Pharmaceutical Sciences;2023-07

3. A Bayesian-based Approach for Identification of Potential Protein Biomarkers in Hepatocellular Carcinoma;Proceedings of the 2023 15th International Conference on Bioinformatics and Biomedical Technology;2023-05-26

4. Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome;Oxidative Medicine and Cellular Longevity;2021-12-31

5. Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma;BMC Cancer;2021-10-29